Lupin launches orphan drug NaMuscla in Germany, UK

01 Feb 2019 Evaluate

Lupin has launched NaMuscla (mexiletine) in Germany and the United Kingdom (UK). NaMuscla is approved across the European Union (EU) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. These disorders are a group of rare, inherited neuromuscular conditions in which myotonia, the inability to relax muscles following voluntary contraction, is the most prominent clinical symptom. NaMuscla reduces myotonia symptoms in adult patients, resulting in a significant improvement in patient quality of life and other functional outcomes.

The launch of NaMuscla in Germany and the UK follows the European Commission’s approval of the product on December 18, 2018. NaMuscla, designated an Orphan Drug by the European Medicines Agency (EMA), is the first treatment to be licensed across the EU for the symptomatic treatment of myotonia in adults with NDM disorders. The product will be commercialized in Germany by Hormosan Pharma GmbH, a full subsidiary of Lupin, and in the UK by Lupin Healthcare (UK).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×